US 11,891,452 B2
Anti-kit antibodies and uses thereof
Yaron Hadari, Harrison, NY (US); Elizabeth M Mandel-Bausch, Pleasant Prairie, WI (US); Francis Joseph Carr, Balmedie (GB); Timothy David Jones, Babraham (GB); and Laura Clare Alexandra Perry, Lidgate (GB)
Assigned to Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed by Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed on Aug. 4, 2020, as Appl. No. 16/984,946.
Application 16/984,946 is a division of application No. 16/221,002, filed on Dec. 14, 2018, granted, now 10,781,267.
Application 16/221,002 is a division of application No. 15/433,482, filed on Feb. 15, 2017, granted, now 10,184,007, issued on Jan. 22, 2019.
Application 15/433,482 is a division of application No. 15/084,715, filed on Mar. 30, 2016, granted, now 9,605,081, issued on Mar. 28, 2017.
Application 15/084,715 is a division of application No. 13/949,931, filed on Jul. 24, 2013, granted, now 9,334,332, issued on May 10, 2016.
Claims priority of provisional application 61/675,762, filed on Jul. 25, 2012.
Claims priority of provisional application 61/675,751, filed on Jul. 25, 2012.
Prior Publication US 2022/0010027 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 31/4045 (2006.01); A61K 31/506 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/566 (2006.01); C07K 16/32 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 31/4045 (2013.01); A61K 31/506 (2013.01); A61K 38/19 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6851 (2017.08); C07K 16/2803 (2013.01); C07K 16/32 (2013.01); C12Y 207/10001 (2013.01); G01N 33/566 (2013.01); G01N 33/5748 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/91205 (2013.01)] 20 Claims
 
1. A method for treating or managing a KIT-associated disorder, wherein the KIT-associated disorder is rheumatoid arthritis, inflammatory bowel disease, asthma, allergic inflammation, a gastrointestinal disorder or mastocytosis, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof, which immunospecifically binds to human KIT and comprises:
(i) a light chain variable region (“VL”) comprising the amino acid sequence:
DIVMTQSPSXK1LSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKXK2LIYSAS YRYSGVPDRFXK3GSGSGTDFTLTISSLQX4EDFAXK5YXK6CQQYNSYPRTEGGG TKVEIK (SEQ ID NO: 12), wherein XK1 is an amino acid with an aromatic or aliphatic hydroxyl side chain, XK2 is an amino acid with an aliphatic or aliphatic hydroxyl side chain, XK3 is an amino acid with an aliphatic hydroxyl side chain, XK4 is an amino acid with an aliphatic hydroxyl side chain or is P, XK5 is an amino acid with a charged or acidic side chain, and XK6 is an amino acid with an aromatic side chain; and
(ii) a heavy chain variable region (“VH”) comprising the amino acid sequence:
QVQLVQSGAEXH1KKPGASVKXH2SCKASGYTFTDYYINWVXH3QAPGKGLEWIA RIYPGSGNTYYNEKFKGRXH4TXH5TAXH6KSTSTAYMXH7LSSLRSEDXH8AVYFCA RGVYYFDYWGQGTTVTVSS (SEQ ID NO: 11), wherein XH1 is an amino acid with an aliphatic side chain, XH2 is an amino acid with an aliphatic side chain, XH3 is an amino acid with a polar or basic side chain, XH4 is an amino acid with an aliphatic side chain, XH5 is an amino acid with an aliphatic side chain, XH6 is an amino acid with an acidic side chain, XH7 is an amino acid with an acidic or amide derivative side chain, and XH8 is an amino acid with an aliphatic hydroxyl side chain.